Orient Pharma Statistics

Total Valuation

Orient Pharma has a market cap or net worth of TWD 6.71 billion. The enterprise value is 7.15 billion.

Market Cap	6.71B
Enterprise Value	7.15B

Important Dates

The last earnings date was Tuesday, April 22, 2025.

Earnings Date	Apr 22, 2025
Ex-Dividend Date	n/a

Share Statistics

Orient Pharma has 223.04 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	223.04M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.08%
Owned by Institutions (%)	n/a
Float	33.55M

Valuation Ratios

The trailing PE ratio is 62.52.

PE Ratio	62.52
Forward PE	n/a
PS Ratio	5.49
PB Ratio	3.76
P/TBV Ratio	5.10
P/FCF Ratio	39.56
P/OCF Ratio	34.08
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 24.47, with an EV/FCF ratio of 42.14.

EV / Earnings	66.59
EV / Sales	5.85
EV / EBITDA	24.47
EV / EBIT	45.28
EV / FCF	42.14

Financial Position

The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.31.

Current Ratio	1.49
Quick Ratio	0.82
Debt / Equity	0.31
Debt / EBITDA	1.87
Debt / FCF	3.22
Interest Coverage	11.31

Financial Efficiency

Return on equity (ROE) is 6.21% and return on invested capital (ROIC) is 4.18%.

Return on Equity (ROE)	6.21%
Return on Assets (ROA)	3.88%
Return on Invested Capital (ROIC)	4.18%
Return on Capital Employed (ROCE)	7.77%
Revenue Per Employee	7.07M
Profits Per Employee	620,659
Employee Count	173
Asset Turnover	0.48
Inventory Turnover	2.22

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +26.21% in the last 52 weeks. The beta is -0.08, so Orient Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.08
52-Week Price Change	+26.21%
50-Day Moving Average	33.92
200-Day Moving Average	32.42
Relative Strength Index (RSI)	43.23
Average Volume (20 Days)	96,486

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Orient Pharma had revenue of TWD 1.22 billion and earned 107.37 million in profits. Earnings per share was 0.48.

Revenue	1.22B
Gross Profit	651.56M
Operating Income	157.91M
Pretax Income	163.12M
Net Income	107.37M
EBITDA	272.67M
EBIT	157.91M
Earnings Per Share (EPS)	0.48

Full Income Statement

Balance Sheet

The company has 109.30 million in cash and 546.49 million in debt, giving a net cash position of -437.19 million or -1.96 per share.

Cash & Cash Equivalents	109.30M
Total Debt	546.49M
Net Cash	-437.19M
Net Cash Per Share	-1.96
Equity (Book Value)	1.79B
Book Value Per Share	8.01
Working Capital	241.18M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 197.01 million and capital expenditures -27.33 million, giving a free cash flow of 169.68 million.

Operating Cash Flow	197.01M
Capital Expenditures	-27.33M
Free Cash Flow	169.68M
FCF Per Share	0.76

Full Cash Flow Statement

Margins

Gross margin is 53.28%, with operating and profit margins of 12.91% and 8.78%.

Gross Margin	53.28%
Operating Margin	12.91%
Pretax Margin	13.34%
Profit Margin	8.78%
EBITDA Margin	22.30%
EBIT Margin	12.91%
FCF Margin	13.88%

Dividends & Yields

Orient Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	1.60%
FCF Yield	2.53%

Stock Splits

The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.

Last Split Date	May 23, 2016
Split Type	Reverse
Split Ratio	0.6500936135

Scores

Orient Pharma has an Altman Z-Score of 4.88.

Altman Z-Score	4.88
Piotroski F-Score	n/a